Topics

Pfizer and Sangamo’s Investigational Hemophilia A Gene Therapy Shows Sustained Increased Factor VIII Levels in Phase 1/2 Results

15:09 EDT 9 Jul 2019 | Speciality Pharma Journal

BRISBANE, Calif. & NEW YORK–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) …

Original Article: Pfizer and Sangamo’s Investigational Hemophilia A Gene Therapy Shows Sustained Increased Factor VIII Levels in Phase 1/2 Results

NEXT ARTICLE

More From BioPortfolio on "Pfizer and Sangamo’s Investigational Hemophilia A Gene Therapy Shows Sustained Increased Factor VIII Levels in Phase 1/2 Results"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...